AnaptysBio, Inc.
ANAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $76 | $22 | $28 | $43 |
| % Growth | 242.8% | -19.8% | -35.6% | – |
| Cost of Goods Sold | $31 | $38 | $41 | $43 |
| Gross Profit | $45 | -$16 | -$13 | $1 |
| % Margin | 58.8% | -69.9% | -48.3% | 1.2% |
| R&D Expenses | $31 | $38 | $41 | $43 |
| G&A Expenses | $10 | $11 | $14 | $10 |
| SG&A Expenses | $10 | $11 | $14 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$31 | -$38 | -$41 | -$43 |
| Operating Expenses | $10 | $11 | $14 | $10 |
| Operating Income | $35 | -$26 | -$28 | -$10 |
| % Margin | 45.5% | -117.5% | -99.2% | -22.4% |
| Other Income/Exp. Net | -$20 | -$12 | -$12 | -$12 |
| Pre-Tax Income | $15 | -$39 | -$39 | -$22 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $15 | -$39 | -$39 | -$22 |
| % Margin | 19.8% | -173.5% | -141.6% | -50.5% |
| EPS | 0.54 | -1.34 | -1.28 | -0.77 |
| % Growth | 140.3% | -4.7% | -66.2% | – |
| EPS Diluted | 0.52 | -1.34 | -1.28 | -0.77 |
| Weighted Avg Shares Out | 29 | 29 | 31 | 30 |
| Weighted Avg Shares Out Dil | 29 | 29 | 31 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $4 | $5 |
| Interest Expense | $23 | $20 | $18 | $17 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $38 | -$18 | -$21 | -$4 |
| % Margin | 50.1% | -82.6% | -74.2% | -8.8% |